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Introduction
Nerve  agents  belong  to  highly  toxic  organophosphorus 
compounds misused as chemical warfare agents for military 
as well as terroristic purposes. Basic mechanism of action 
of nerve agents is based on acetylcholinesterase (AChE, EC 
3.1.1.7) inhibition and subsequent accumulation of neuro-
mediator acetylcholine at the cholinergic synapses, either 
peripheral or central leading to cholinergic hyperstimula-
tion and development of symptoms of poisoning, followed 
by  metabolic  dysbalance  and  death  without  effective 
prophylaxis/treatment. The antidotal treatment of acute 
poisonings with nerve agents still represents a serious prob-
lem and, therefore, we are searching how to satisfactorily 
protect people against acute toxicity of nerve agents. There 
are two approaches how to improve the medical protection 
against nerve agents: 
•  to increase the resistance of nerve agent-exposed organ-
ism and the efficacy of post-exposure antidotal treatment 
by pharmacological prophylaxis 
•  the development of new, more effective antidotes, expe-
cially AChE reactivators, to achieve the satisfactorily 
effective antidotal treatment of acute poisonings with 
nerve agents. 
Prophylaxis of Nerve Agent Exposure
Prophylaxis  against  nerve  agents  is  based  on  various 
approaches: keeping AChE, key enzyme for toxic action 
of  nerve  agents  intact  (protection  of  cholinesterases) 
is a basic requirement for effective prophylaxis. It can 
be  reached  using  reversible  inhibitors  (preferably  car-
bamates). AChE inhibited by carbamates is resistant to 
nerve  agent  inhibition.  After  spontaneous  recovery  of 
the activity (decarbamylation), normal AChE serves as a 
source of the active enzyme. Pyridostigmine is the most 
promising carbamate especially against soman poisoning 
(Gordon et al., 1978; Kassa et al., 2001). It was introduced 
into some armies as a prophylactic drug against nerve 
agents. Its prophylactic effect (like the effects of other 
carbamates) is limited by its dose. With a higher dose, a 
higher efficacy was observed, but the side effects were more 
expressed, too. This problem can be solved by the adding 
of pyridostigmine antagonizing drugs – anticholinergics. 
The  prophylactic  combination  of  pyridostigmine  with 
trihexyphenidyle and benactyzine was introduced into 
the Czech Army as PANPAL. The presence of these two 
anticholinergics allowed us to increase the pyridostigmine 
dose and to increase its prophylactic efficacy without side 
effects as it has been demonstrated on volunteers (Bajgar, 
2004; Fusek et al., 2006). Other carbamates also have a 
good prophylactic efficacy, especially physostigmine (due 
to its central effect on the contrary to pyridostigmine) 
(Bajgar, 2004; Bajgar et al., 2007a; Patocka et al., 2006). 
Structurally different inhibitors from the carbamate and 
organophosphate groups were also studied. Among these 
compounds (preferably binding to the AChE anionic site), 
tacrine, 7-MEOTA and huperzine A were considered and 
experimentally studied with respect to prophylaxis in vitro 
and in vivo. The most interesting results were obtained 
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with huperzine A (Bajgar et al., 2007b; Gordon et al., 2005; 
Lallement et al., 2002). 
Detoxification principle can be used in two different 
ways: administration of enzymes splitting nerve agents or 
specific enzymes which bind nerve agents (cholinesterases). 
Nerve agents are bound to the exogenously administered 
enzyme and thus the nerve agent level in the organism is 
decreased (it acts as “scavenger”). Enzymes hydrolysing 
nerve agents are under research. The administration of 
enzymes  (AChE  and  butyrylcholinesterase,  BuChE,  EC 
3.1.1.8) as scavengers seems to be very promising. They are 
acting at the very beginning of the toxic action, without 
interaction with the target tissues and without side effects. 
All of these features are of great interest and they are yield-
ing practical results – isolation of the enzyme, examina-
tion for lack of and auto immune response, stability, and 
establishment of pharmacokinetic and pharmacodynamic 
properties. Moreover, BuChE pretreatment also showed 
protective effects on AChE inhibition in the brain parts fol-
lowing low level sarin inhalation exposure (Sevelova et al., 
2004). Given our increasing knowledge in bioengineering 
and biotechnology, it would be possible to obtain a modified 
enzyme splitting nerve agents and simultaneously reacting 
with nerve agents as a scavenger (Bajgar et al., 2007c; Doctor 
et al., 1991, 1997; Saxena et al., 2004). 
The antidotes currently used for the treatment of nerve 
agent poisoning can be tested as prophylactics. This princi-
ple can be considered as a treatment “in advance”. Standard 
antidotes were studied in this respect i.e. anticholinergics, 
reactivators,  anticonvulsants  and  others.  The  problem 
with their use is the timing, duration and achievement of 
sufficient levels of these antidotes after the administration. 
The prolongation of the duration of the antidotal effects 
by achievement of their sufficient level in the blood by oral 
administration is not always possible, especially for reacti-
vators. There is a reason for searching for other routes of 
administration. Transdermal administration of one of the 
most effective reactivators (HI-6) was shown to be the most 
realistic approach. The final result was the new prophylactic 
transdermal antidote TRANSANT containing the reactiva-
tor HI-6. This preparation was clinically tested (including 
dermal sensitivity) without any harmful effects; field testing 
was also successful and TRANSANT was introduced into 
the Czech Army (Bajgar, 2004; Fusek et al., 2007) . 
Combinations of these approaches and use of different 
drugs are also possible. Benzodiazepines, calcium antago-
nists, neuromuscular blockers, adamantanes, and the opiate 
antagonists were tested with different results but they are 
not very useful for practical use. There are other combina-
tions such as an administration of triesterase, procyclidine, 
clonidine, sustained release of physostigmine and scopol-
amine. However, all these studies are just experimental and 
they have not reached the practical output stage (Bajgar, 
2004). Only three prophylactics have been introduced into 
the armies – PYRIDOSTIGMINE BROMIDE, PANPAL 
(tablets containing pyridostigmine, trihexyphenidyle and 
benactyzine), TRANSANT (transdermal patch containing 
HI-6) are means introduced into different armies as prophy-
lactics at present. It appears from these results that simple 
prophylaxis (without postexposure treatment) against nerve 
agents is not sufficient enough. Future development will 
be focused on scavengers (cholinesterases and modified 
enzymes) and other drugs – preferably reversible cholines-
terase inhibitors (e.g. huperzine A, physostigmine, acridine 
derivatives etc.). 
The Evaluation of Reactivating 
Efficacy of New Oximes In Vitro 
Generally, the design of new pharmaceutically active com-
pounds is based on computational approaches such as dock-
ing studies, prediction of active compounds using different 
predictive approaches or structure-activity relationship. 
These tools are used for the development of new AChE 
reactivators, too (Dohnal et al., 2005). The most important 
part influencing further design of new AChE reactivators 
at our department is the structure-activity relationship 
study. In this part, we have focused our attention on several 
structural requirements which are the most important for 
the sufficient reactivation potency of used oximes. Among 
them, the presence of the quaternary nitrogen (needed for 
the affinity to intact and inhibited enzyme), the presence of 
the oxime group (needed for the breaking of the nerve agent-
enzyme complex) and the length of the linker between two 
pyridinium rings (influencing affinity towards the enzyme) 
are the most important (Kuca et al., 2006).
To evaluate the reactivating efficacy of newly developed 
and currently available oximes in vitro, the brain homo-
genate (0.5 ml) is treated with solution (0.5 ml) of nerve 
agent in appropriate concentration for 30 min. Afterwards, 
reaction solution is adjusted to 23 ml with 0.3 M sodium 
chloride.  Then,  0.02 M  solution  of  acetylcholine  iodide 
(2 ml) is added to the mixture. The liberated acetic acid is 
titrated with 0.01 M sodium hydroxide on an RTS 822 titra-
tor (Radiometer, Denmark) in the pH-stat mode (pH 8.0) at 
room temperature (25 °C). The slope of the linear part of the 
time dependence of the sodium hydroxide used represents 
the activity of the inhibited enzyme (in fact, the initial rate 
of the enzymatic reaction). Resulted inhibition of AChE is 
set to 95%. Reactivation of inhibited AChE is performed 
immedi  ately after its inhibition. A solution (1 ml) of the reac-
tivator in appropriate concentration is added to the inhibited 
enzyme. After 10 min reactivation at 25 °C, the mixture 
is adjusted to 23 ml with 0.3 M sodium chloride solution. 
Then, 0.02 M solution of acetylcholine iodide (2 ml) is added 
and immediately afterwards the activity of the reactivated 
enzyme is determined by above described potentiostatic 
method (Kuca and Kassa, 2003). The screening test is used 
as the first step of evaluation of the large quantity of new 
oximes to reactivate nerve agent-inhibited AChE in vitro. 
As the results, we have obtained a percentage of reactiva-
tion. Only promising oximes together with standards are 
tested in the second step of in vitro investigation where their 
kinetic parameters of reactivation are calculated. 
Regarding  the  structure-activity  relationship  study, 
many AChE reactivators were prepared in the last decade. 
Their design was targeted towards nerve agents (especially 20
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tabun) as well as organophosphorus pesticides. In general, 
the  monoquaternary  salts  (analogues  of  pralidoxime) 
were replaced by bisquaternary reactivators (analogues of 
trimedoxime and obidoxime). Namely, the symmetrical 
molecules with two oximes were used in effort to extend 
the reactivation potency (Musilek et al., 2006; Musilek et 
al., 2007a). Based on previous results, the further design was 
adapted for bisquaternary compounds with one oxime and 
modified non-oxime part of the molecule (Musilek et al., 
2007b).
The synthesis of new reactivators and the evaluation 
of their reactivating efficacy in vitro resulted in several 
promising compounds. The first generation is represented 
by K027 and K048 (Kuca et al., 2003), which were found to 
be effective especially against organophosphorus pesticides 
and less toxic than most currently available compounds. 
The second generation of oximes is represented by K074 
and K075 (Kuca et al., 2005), which extend the reactivation 
potency of obidoxime and trimedoxime, however, they were 
highly toxic. Recently, the third generation was developed 
from all previous results and the best compound against 
tabun-inhibited AChE was called K203 (Musilek  et al., 
2007c). This compound is well balanced in case of reactiva-
tion activity and its toxicity compared to commonly used 
reactivators. Thus, K203 seems to be very promising oxime 
among reactivators of tabun-inhibited AChE.
The Evaluation of Reactivating and 
Therapeutic Efficacy of New Oximes In Vivo
According to in vitro results, the most promising reactiva-
tors were subjected to the in vivo studies (toxicity test, the 
evaluation of therapeutic, reactivating and neuroprotective 
efficacy) and their potency to counteract the acute toxicity 
of nerve agents is compared to the therapeutic and reac-
tivating efficacy of commonly used oximes – obidoxime, 
trimedoxime and the oxime HI-6. 
Before  starting  the  evaluation  of  reactivating  and 
therapeutic efficacy of all newly developed oximes, the 
acute toxicity of oximes in rats and mice is evaluated by 
the assessment of the LD50 values and their 95% confidence 
limit using probit-logarithmical analysis of death occurring 
within 24 hr after i.m. administration of oxime at 5 different 
doses with 8 animals per dose (Tallarida and Murray, 1987). 
To evaluate the therapeutic efficacy of newly developed 
oximes against supralethal poisoning with nerve agent in 
mice was evaluated by the assessment of the LD50 values and 
their 95% confidence limit using probit-logarithmical analy-
sis of death occurring within 24 hr after i.m. administration 
of nerve agent at 5 different doses with 8 animals per dose 
(Tallarida and Murray, 1987). To evaluate their therapeutic 
efficacy, the oximes were i.m injected at equitoxic doses cor-
responding to 5% of their LD50 value in combination with 
atropine (21 mg/kg) 1 min after nerve agent administration. 
The influence of the nature of the antidotal treatment was 
expressed as protective ratio (LD50 value of treated mice/ 
LD50 value of untreated mice).
To evaluate the reactivating efficacy of the oximes, the 
rats are injected i.m. with either atropine (21 mg/kg) alone or 
atropine (21 mg/kg) in combination with one of the oximes 
studied at equitoxic doses corresponding to 5% of their LD50 
value 5 min before intramuscular nerve agent poisoning 
in rats. The control rats are administered i.m. with saline 
instead of nerve agent and antidotes at the same volume. 
The rats are decapitated and exsanguinated to obtain the 
blood 30 min following nerve agent poisoning at a dose 
corresponding to LD50. The diaphragms and brains are 
removed and homogenized in distilled water to determine 
AChE activity by a spectrophotometric method (Ellman 
et al., 1961). The reactivation rate (%) is calculated using 
the AChE activity values: {1 – [((saline control) – (oxime 
+ atropine))/((saline control) – (atropine control))]} × 100 
(Clement et al., 1992). The AChE activity is expressed as 
µkat/kg or L (µmol substrate hydrolyzed/kg wet tissue or 
L blood/s).
The development of new oximes is especially directed 
for  the  antidotal  treatment  of  acute  tabun  poisoning 
because  deleterious  effects  of  tabun  (O-ethyl-N,N-
dimethylphosphoramido-cyanidate) are extraordinarily dif-
ficult to antagonize due to the changes in hydrogen bonding 
and the conformational changes of AChE-tabun complex 
after aging process in the AChE active site that make the 
nucleophilic attack of oxime almost impossible (Ekström 
et al., 2006). According to in vitro results, one of the most 
promising oximes for antidotal treatment of acute tabun poi-
soning is K203 [1-(4-carbamoylpyridinium)-4-(4-hydroxy-
iminomethyl-pyridinium)-but-2-ene dibromide]. The results 
show that the acute toxicity of the newly developed oxime 
K203 is a little higher than the acute toxicity of obidoxime 
and trimedoxime in mice but it is significantly lower than 
the acute toxicity of obidoxime and trimedoxime in rats. 
The oxime K203 is able to significantly reactivate tabun-
inhibited AChE in blood, diaphragm and brain. Its reacti-
vating efficacy is higher in comparison with the potency of 
obidoxime and trimedoxime to reactivate tabun-inhibited 
AChE in diaphragm and brain, but the difference in their 
reactivating potency is significant in brain only. On the 
other hand, the oxime HI-6 is considered to be the worst 
reactivator of tabun-inhibited AChE among currently avail-
able oximes (Kassa et al., 2008). These results correlate with 
the therapeutical potency of the oximes tested against lethal 
tabun poisoning in mice. The potency of newly developed 
oxime K203 to eliminate lethal toxic effects of tabun in mice 
was significantly higher in comparison with all commonly 
used oximes studied. It was able to decrease acute toxicity of 
tabun nearly two times. On the other hand, the oxime HI-6 
showed significantly lower potency to eliminate lethal toxic 
effects of tabun in mice in comparison with other studied 
oximes (Kassa et al., 2008). 
Thus, the newly developed oxime K203 seems to be 
significantly more efficacious to reactivate tabun-inhibited 
AChE in rats and to eliminate lethal toxic effects of tabun 
in mice than all currently available oximes and, therefore, it 
is suitable for the replacement of commonly used oximes for 
the treatment of acute tabun poisoning. 21
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